• c-Myc Tag Peptide: From Assay Control to Translation

  2026-08-20

  A strategic guide to using the c-Myc tag Peptide as an epitope-specific assay control, while connecting measurement rigor to broader questions of transcription factor stability, immune signaling, and translational reproducibility.

• HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody

  2026-08-20

  The HyperFluor 488 Goat Anti-Human IgG (H+L) Antibody translates variant-aware immunology into sensitive, species-conscious antibody detection. Learn how its H+L specificity, Alexa Fluor 488 signal, and workflow flexibility support human IgG measurements without confusing binding data with neutralization.

• Influenza Hemagglutinin (HA) Peptide Workflow

  2026-08-19

  Use the HA tag peptide for controlled capture, native-compatible elution, and orthogonal validation of protein interactions. This workflow shows how it can support mechanistic studies of NEDD4L–PRMT5 signaling without confusing tagged-protein recovery with proof of biological causality.

• V5 Epitope Tag Peptide: Mechanism and Workflow

  2026-08-19

  The V5 Epitope Tag Peptide contains the 14-residue GKPIPNPLLGLDST peptide used as an antibody-recognized epitope in recombinant protein workflows. Its defined composition, high reported purity, and solvent-specific solubility support controlled protein tagging for Western blot, immunoprecipitation, and related detection assays.

• Danazol and HPG-Axis Models: From Drug to Probe

  2026-08-18

  Danazol is more than a weak androgenic steroid: it is a versatile perturbation tool for studying steroidogenesis, LH feedback, and puberty-related endocrine phenotypes. This guide connects molecular mechanism with the 2025 danazol-induced rat model and practical assay design.

• RSL3: GPX4 Inhibitor Workflows for Ferroptosis

  2026-08-18

  RSL3 provides a direct way to stress the GPX4-dependent lipid peroxide defense system, enabling ferroptosis studies in RAS-driven cancer models and radiation-response assays. This guide connects practical dosing, orthogonal readouts, rescue controls, and the HIF-1α-HILPDA findings reported in nasopharyngeal carcinoma.

• Tranexamic Acid: From Clot Stability to Translation

  2026-08-17

  Tranexamic Acid is more than a clot-stabilizing reagent: it is a mechanistic bridge between fibrinolysis research, biomaterial design, and translational hemostasis. This article examines plasmin inhibition, evidence from antibacterial wound dressings, assay strategy, product selection, and the limitations that should guide the next generation of research.

• KAS-ATAC Sequencing Maps Accessible ssDNA in Chromatin

  2026-08-17

  The KAS-ATAC protocol combines ATAC-seq transposition with N3-kethoxal labeling to identify genomic fragments that are both physically accessible and enriched for single-stranded DNA. Marinov and Greenleaf describe the chemistry, enrichment, library preparation, and analysis considerations needed to interpret this intersection as a readout of regulatory accessibility and transcription-associated DNA structures.

• MLN2238 Proteasome β5 Inhibitor Workflow

  2026-08-16

  MLN2238 enables controlled chymotrypsin-like proteasome inhibition for apoptosis, proteostasis, and drug-resistance studies. Its use in ROS/JNK/CREB experiments also connects direct target engagement with stress-adaptation phenotypes in oncology and model-organism research.

• KU-55933: Practical ATM Kinase Inhibition Workflows

  2026-08-15

  Use KU-55933 to connect ATM signaling with Akt phosphorylation, cell-cycle behavior, viability, and metabolic phenotypes in reproducible cell-based assays. This guide combines product-specific handling with a personalized-model framework inspired by an iPSC prescreening study, while clearly separating established evidence from workflow recommendations.

• Carrier-Free Triterpene Prodrug for OSCC

  2026-08-14

  This ACS Applied Materials & Interfaces study developed a carrier-free, self-assembled prodrug from glycyrrhetinic acid, ginsenoside Rh2, and a ROS-cleavable thioketal linker for oral squamous cell carcinoma therapy. Its central innovation is a self-reinforcing mechanism in which tumor-associated ROS triggers drug release while liberated glycyrrhetinic acid generates additional ROS, strengthening apoptosis and reducing reliance on conventional nanocarriers.

• Deferiprone: Designing Iron-Stress Assays

  2026-08-14

  Deferiprone enables controlled investigation of iron-stress phenotypes rather than simple cytotoxicity. This guide translates enterocyte metabolomics into practical assay design for cancer biology, apoptosis, oxidative stress, and translational models.

• Cyclosporin A: Mechanism, Evidence, and Research Use

  2026-08-13

  Cyclosporin and Cyclosporin A are cyclophilin-directed immunosuppressive compounds used to study calcineurin–NFAT signaling, T-cell activation, and mitochondrial permeability transition. The strongest mechanistic evidence identifies Cyclophilin A as the principal mediator of cyclosporine-dependent immunosuppression in the tested mouse and T-cell models.

• FLAG tag Peptide for Myelin Protein Assays

  2026-08-13

  Learn how the FLAG tag Peptide (DYKDDDDK) can connect recombinant protein detection with mechanistic studies of oligodendrocyte differentiation. This article translates recent NMD–Hnrnpl–Mag findings into practical tag design, purification, elution, and assay-validation decisions.

• How Kinase Inhibitors Tune p38α Dephosphorylation

  2026-08-12

  A 2024 bioRxiv study shows that some kinase inhibitors can do more than occupy the p38α active site: they can stabilize an activation-loop conformation that accelerates dephosphorylation by WIP1. Biochemical experiments and X-ray structures establish a conformational mechanism that may guide more specific kinase-inhibitor design, while the preprint does not by itself validate applications in cells, animals, or disease models.

16174 records 1/1079 page Next 12345 下5页 Last page